西米普利单抗联合peltopepimut-S疫苗治疗复发性宫颈癌:一项2期临床试验
这项全球2期开放标签研究纳入113例一线化疗后进展的复发性HPV16阳性宫颈癌患者,给予peltopepimut-S疫苗3剂(第1、29、50天)联合西米普利单抗350 mg每3周一次直至疾病进展。研究者评估的客观缓解率为16.8%(95%CI 9.9-23.7),中位缓解持续时间5.6个月,中位总生存期13.3个月,中位无进展生存期3.0个月。结论认为该联合方案获益与西米普利单抗单药相似,肿瘤细胞PD-L1表达较高者可能更可能获益。
要点
- 复发性HPV16阳性宫颈癌一线化疗进展后,西米普利单抗联合peltopepimut-S疫苗的客观缓解率为16.8%(95%CI 9.9-23.7)。
- 鳞癌患者中,肿瘤细胞PD-L1<1%者客观缓解率15.8%,PD-L1≥1%者24.1%。
- 治疗中出现不良事件发生率为92.9%,最常见为注射部位反应(38.9%)和贫血(25.7%),6例(5.3%)死于治疗中出现的不良事件。
核心结论
- 西米普利单抗联合peltopepimut-S疫苗提供的获益与西米普利单抗单药相似;肿瘤细胞PD-L1表达较高的患者可能更可能从治疗中获益。
研究设计与样本
- 全球2期开放标签研究(NCT04646005),纳入一线化疗后疾病进展的复发性HPV16阳性宫颈癌患者113例,2021年6月28日至2023年5月22日入组。
- 患者接受peltopepimut-S疫苗共3剂,分别在第1、29、50天给药,并接受西米普利单抗350 mg每3周一次直至疾病进展或其他原因提前终止。
- 主要终点为按RECIST版本1.1由研究者评估的客观缓解率;次要终点为缓解持续时间、总生存期、无进展生存期和安全性。
主要发现
- 入组患者中80.5%为白人,中位年龄49.0岁,58.4%的ECOG体能状态评分为0,中位随访时间4.9个月。
- 研究者评估的客观缓解率为16.8%(95%CI 9.9-23.7)。
- 鳞状细胞癌患者中,肿瘤细胞PD-L1<1%者的客观缓解率为15.8%,PD-L1≥1%者为24.1%。
- 中位缓解持续时间为5.6(95%CI 3.5-不可估计)个月,中位总生存期为13.3(95%CI 10.8-16.3)个月,中位无进展生存期为3.0(95%CI 1.7-4.0)个月。
- 治疗中出现的不良事件发生率为92.9%,最常见为注射部位反应(38.9%)和贫血(25.7%);6例(5.3%)患者死于治疗中出现的不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the clinical benefit of cemiplimab+peltopepimut-S vaccine after disease progression on first-line chemotherapy. METHODS: This global phase 2 open-label study (NCT04646005) recruited patients with recurrent HPV16+ cervical cancer who had previously experienced disease progression after first-line chemotherapy. Patients received a total of 3 doses of peltopepimut-S vaccine on days 1, 29, and 50 and cemiplimab 350 mg every 3 weeks until disease progression or other reason for early discontinuation. Primary endpoint was objective response rate (ORR) per RECIST version 1.1; secondary endpoints were duration of response (DOR), overall survival (OS), progression-free survival (PFS), and safety. RESULTS: Of 113 patients enrolled between June 28, 2021 and May 22, 2023, 80.5 % were white, with a median age of 49.0 years, and 58.4 % had an ECOG PS of 0. Median duration of follow-up was 4.9 months. ORR (95 % CI) per investigator assessment was 16.8 % (9.9-23.7). ORR of patients with squamous cell carcinoma by PD-L1 expression in tumor cells was 15.8 % for patients with PD-L1 < 1 % and 24.1 % for patients with PD-L1 ≥ 1 %. Median (95 % CI) DOR was 5.6 (3.5-not estimable) months. Median (95 % CI) OS and PFS were 13.3 (10.8-16.3) months and 3.0 (1.7-4.0) months, respectively. Treatment-emergent adverse events (TEAEs) occurred in 92.9 % of patients, the most common being injection-site reaction (38.9 %) and anemia (25.7 %). Six (5.3 %) patients died from a TEAE. CONCLUSION: Cemiplimab+peltopepimut-S vaccine provides similar benefits to cemiplimab monotherapy; patients with higher PD-L1 expression in tumor cells may be more likely to benefit from treatment.
引用
- Lorusso D, Oaknin A, Borges GS, et al. Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial. Gynecol Oncol. 2025. PMID: 40154184. doi:10.1016/j.ygyno.2025.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。